.[J] Chinese Pharmaceutical Journal, 2011,V46(12): 917-920
��
[1]
KHOSLA S��WESTENDORF J J��OURSLER M J. Building bone to reverse osteoporosis and repair fractures[J]. J Clin Invest��2008��118(2��421-428.[2] SUBBIAH V��MADSEN V S��RAYMOND A K��et al. Of mice and men�� divergent risks of teriparatide-induced osteosarcoma [J]. Osteoporos Int��2010��21(6��1041-1045.[3] GLASS D A��KARSENTY G. In vivo analysis of Wnt signaling in bone[J]. Endocrinology��2007��148(6�� 2630-2634.[4] KENNELL J A��MACHOUGALD O A. Wnt signaling inhibits adipogenesis through beta-catenin-dependent and -independent mechanisms[J]. J Biol Chem��2005��280(25�� 24004-24010.[5] BENNETT C N��LONGO K A��WRIGHT W S��et al. Regulation of osteoblastogenesis and bone mass by Wnt10b[J]. Proc Natl Acad Sci USA��2005��102(9�� 3324-3329.[6] LONGO K A��WRIGHT W S��KANG S��et al. Wnt10b inhibits development of white and brown adipose tissues[J]. J Biol Chem��2004��279(34�� 35503-35509.[7] ROSS S E��HEMATI N��LONGO K A��et al. Inhibition of adipogenesis by Wnt signaling[J]. Science��2000�� 289(5481�� 950-953.[8] MBALAVIELE G��SHEIKH S��STAINS J P��et al. Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation[J]. J Cell Biochem��2005��94(2�� 403-418.[9] GLASS D A 2ND��BIALEK P��AHN J D��et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation[J]. Dev Cell��2005��8(5�� 751-764.[10] VANDER HORST G��VANDERWERF S M��FARIH-SIPS H��et al. Downregulation of Wnt signaling by increased expression of Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells[J]. J Bone Miner Res��2005��20(10�� 1867-1877.[11] SEMENOV M V��HE X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST[J]. J Biol Chem��2006��281(50�� 38276-38284.[12] ELLIES D L��VIVIANO B��MCCARTHY J��et al. Bone density ligand Sclerostin.directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity[J]. J Bone Miner Res��2006��21(11�� 1738-1749.[13] HENRIKSEN K��GRAM J��HOEGH-ANDERSEN P��et al. Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro��but have decreased resorption capacity in vivo[J]. Am J Pathol��2005��167(5�� 1341-1348.[14] HOLMEN S L��GIAMBERNARDI T A��ZYLSTRA C R��et al. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6[J]. J Bone Miner Res��2004��19(12�� 2033-2040.[15] MANI A��RADHAKRISHNAN J��WANG H��et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors[J]. Science��2007��315(5816�� 1278-1282.[16] WAN M��YANG C��LI J��et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6[J]. Genes Dev��2008��22(21�� 2968-2979.[17] YADAV V K��RYU J H��SUNDA N��et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum[J]. Cell��2008��135(5�� 825-837.[18] KULKARNI N H��ONYIA J E��ZENG Q��et al. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo[J]. J Bone Miner Res�� 2006��21(6��910-920.[19] GARDNER J C��VANBEZOOIJEN R L��MERVIS B��et al. Bone mineral density in sclerosteosis�� affected individuals and gene carriers[J]. J Clin Endocrinol Metab��2005��90(12�� 6392-6395.[20] REPPE S��REFVEM H��GAUTVIK V T��et al. Eight genes are highly associated with BMD variation in postmenopausal Caucasian women[J]. Bone��2010��46(3��604-612. [21] LIN C��JIANG X��DAI Z��et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling[J]. J Bone Miner Res��2009��24(10��1651-1661.[22] AI M��HOLMEN S L��VANHUL W��et al. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling[J]. Mol Cell Biol��2005��25(12�� 4946-4955.[23] DAVIDSON G��MAO B��DELBARCO B I��et al. Kremen proteins interact with Dickkopf1 to regulate anteroposterior CNS patterning[J]. Development��2002��129(24�� 5587-5596.[24] ELLWANGER K��SAITO H��CLEMENT L P��et al. Targeted disruption of the Wnt regulator Kremen induces limb defects and high bone density[J]. Mol Cell Biol��2008��28(15�� 4875-4882.[25] SEMENOV M V��ZHANG X��HE X. DKK1 antagonizes Wnt signaling without promotion of LRP6 internalization and degradation[J]. J Biol Chem��2008��283(31�� 21427-21432.[26] WANG K��ZHANG Y��LI X��et al. Characterization of the Kremen-binding site on Dkk1 and elucidation of the role of Kremen in Dkk-mediated Wnt antagonism[J]. J Biol Chem��2008��283(34�� 23371-23375.[27] CAO J J��SINGLETON P A��MAJUMDAR S��et al. Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44[J]. J Bone Miner Res��2005��20(1�� 30-40.[28] LI X��LIU P��LIU W��et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation[J]. Nat Genet��2005��37(9�� 945-952.[29] BODINE P V��STAUFFER B��PONCEDELEON H��et al. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation[J]. Bone��2009��44(6��1063-1068. [30] BOVOLENTA P��ESTEVE P��RUIZ J M��et al. Beyond Wnt inhibition�� new functions of secreted Frizzled-related proteins in development and disease[J]. J Cell Sci��2008��121(Pt 6��737-746.
2011, Vol. 46 
